olaparib
Lynparza Benefit in Early BRCA-Mutated Breast Cancer Reignites Universal Genetic Testing Discussion
Premium
The OlympiA trial showed a disease-free survival benefit with adjuvant PARP inhibitor therapy for early-stage, BRCA1/2-mutated, HER2-negative breast cancer patients.
Uterine Leiomyosarcoma Sequences Point to Potentially Targetable Somatic Mutations
Using genome, exome, or transcriptome sequences from dozens of uterine leiomyosarcoma samples, researchers found alterations that may respond to existing targetable treatments.
Myriad Genetics Expands MyChoice CDx Access Through Partnerships in Europe, China
A deal with Burning Rock will allow the test to be used in trials and clinics in China, and Myriad will license its technology to French and German pathology labs.
FDA Approves Foundation Medicine Liquid Biopsy Test as CDx for Lynparza
The test will use a blood-based biopsy to detect patients with BRCA1, BRCA2, and/or ATM alterations in metastatic castration-resistant prostate cancer.
Medicare to Cover Myriad Genetics' BRACAnalysis for FDA-Approved CDx Indications
In a local coverage article, Medicare contractors in the MolDx program added prostate cancer to the covered indications for the test.